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Abstract
Introduction: Stroke, due to its worldwide prevalence, is not only a medical challenge, but also a serious social problem. Recently, ongoing 
research has examined whether there are associations between adipose tissue hormones and the risk, mechanisms and course of stroke. 
The aim of our study was to determine whether there are significant differences in blood concentrations of insulin, adiponectin, leptin, 
resistin and in insulin resistance among patients in the acute phase of ischaemic stroke, compared to healthy subjects. In addition, we 
wanted to investigate if those biochemical values show a correlation with the neurological condition of our patients.
Material and methods: Adiponectin, leptin, resistin and insulin were measured in patients (n = 69) with first-ever ischaemic stroke (con-
firmed by CT), using specific electrochemoluminescence, radioimmunoassay and ELISA methods. Neurological evaluation was performed 
using Barthel ADL index on the day of admission and on the ninth day of hospitalisation. Insulin resistance value was obtained via the 
HOMA-IR calculator. Data was compared to that of healthy individuals (n = 26).
Results: Insulin concentration (51.08 v. 17.02 uU/mL) and HOMA-IR value (6.3 v. 2.2) were significantly higher in the study group. Leptin 
(14.98 v. 10.47 ng/mL) and resistin (28.92 v. 12.25 ng/mL) levels were elevated among the stroke survivors compared to controls, but no 
significant difference was noted in adiponectin. Negative correlations of adiponectin level and Barthel score were observed.
Conclusions: Hyperinsulinaemia and insulin resistance are involved in the pathogenesis of ischaemic stroke. Hyperleptinaemia and 
hyperresistinaemia play a role in the mechanism of stroke. The severity of stroke is associated with adiponectin blood concentration. 
(Endokrynol Pol 2012; 63 (5): 338–345)
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Streszczenie
Wstęp: Udar mózgu stanowi częstą przyczynę zgonów oraz najczęstszą przyczynę trwałej niesprawności u osób powyżej 40. roku życia. 
Od kilku lat badana jest rola adipocytokin w patogenezie chorób OUN. Celem pracy jest próba odpowiedzi na pytanie, czy istnieją róż-
nice w stężeniach adiponektyny, leptyny, rezystyny i insuliny we krwi między chorymi w ostrej fazie niedokrwiennego udaru mózgu 
a osobami zdrowymi oraz czy istnieje związek między stężeniami wyżej wymienionych hormonów we krwi a stanem neurologicznym 
chorych, ocenianym za pomocą skali Bartel w momencie rozpoczęcia leczenia oraz dalszej obserwacji. 
Materiał i metody: Badanie przeprowadzono u 69 chorych (37 kobiet, śr. wieku 72 lata, 32 mężczyzn, śr. wieku 68 lat) z objawami udaru 
niedokrwiennego mózgu. U wszystkich chorych wykonano TK mózgu, dokonano oceny stanu neurologicznego przy przyjęciu oraz 
w 9. dobie leczenia za pomocą skali „ciężkości udaru” według Bartela oraz oznaczono we krwi stężenia adiponektyny, leptyny, rezystyny i insuliny.
Wyniki: Nie stwierdzono różnicy w stężeniu adiponektyny we krwi między grupą z niedokrwiennym udarem mózgu a grupą kontrolną 
(15.49 v. 14.32 ug/mL). Stężenia leptyny (14.98 v. 10.47 ng/mL), rezystyny (28.92 v. 12.25 ng/mL), insuliny (51.08 v. 17.02 uU/mL) oraz wskaźnik 
insulinooporności HOMA (6.3 v. 2.2) u chorych z niedokrwiennym udarem mózgu były większe niż u osób zdrowych. Stwierdzono ujemną 
korelację pomiędzy wartością skali Bartel a stężeniem adiponektyny u chorych z udarem niedokrwiennym zarówno w dniu przyjęcia 
(R –0.266, p < 0.05), jak i w 9 dobie leczenia (R –0.302, p < 0.05). 
Wnioski: Wydaje się, że zarówno hiperinsulinemia i insulinooporność, jak i hiperleptynemia oraz hiperezystynemia odgrywają rolę 
w patogenezie niedokrwiennego udaru mózgu. Stopień ciężkości udaru w momencie wystąpienia oraz jego przebieg jest z kolei związany 
ze stężeniem adiponektyny we krwi. (Endokrynol Pol 2012; 63 (5): 338–345)
Słowa kluczowe: udar niedokrwienny, adiponektyna, leptyna, rezystyna, insulina, HOMA 
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Introduction
Stroke is the third commonest cause of death in Western 
countries, after heart diseases and neoplastic diseases. It 
is also a leading cause of chronic disability among people 
over 40 years of age. In Poland, stroke incidence reaches 
177.3/100,000 among men and 125/100,000 among women 
[1]. These numbers are similar to those occurring in other 
European countries. The two main types of stroke are 
ischaemic stroke, which accounts for about 80% of all 
cases, and hemorrhagic stroke, representing about 20% [2].
Progress in stroke treatment methods has been 
reflected in long-term studies, which show a decrease 
in mortality occurring in Western countries [3, 4]. Un-
fortunately, in Poland, the stroke mortality rate still 
remains much worse, being 106.4/100,000 in men and 
78.7/100,000 in women [1]. It is estimated that about 
400,000 people in Poland live with the permanent 
consequences of a stroke. These values mean that the 
prevention, diagnosis and therapy of stroke is not only 
a medical challenge, but also a significant social problem.
Adipocytokines are signalling proteins, secreted by 
adipose tissue, which act in paracrine and endocrine 
ways [5–10]. Recently, they have aroused the interest 
of scientists due to their multiple features. Many pub-
lications dealing with vascular diseases have claimed 
a link between the substances produced by fat tissue 
and coronary artery disease, hypertension, metabolic 
syndrome and venous thrombosis [5, 11–21]. Some of 
them also present results showing relationships be-
tween adipokines and stroke [22–28]. That is why we 
decided to investigate the behaviour of the discussed 
cytokines in a group of acute ischaemic stroke survivors.
In recent years, many studies have shown that 
fatty tissue is not only an energy storage organ, 
but also a complex and highly metabolically active 
endocrine organ. This tissue, apart from adipocytes, 
also contains connective tissue matrix, nerve tissue, 
stromo-vascular cells and immune system cells [8]. In 
physiologic conditions, fat constitutes 10–25% of total 
body mass, 85% of which is subcutaneous adipose 
tissue and 15% visceral adipose tissue. These values 
clearly indicate the crucial role of adipose tissue as 
the largest endocrine gland. From many substances 
secreted from this tissue, the most important are 
adiponectin, leptin, resistin, plasminogen activator 
inhibitor 1 (PAI-1), tumour necrosis factor a (TNF-a), 
complement system proteins and RAA (renin-angio-
tensin-aldosterone) axis proteins [11, 29].
The biological activity of adipokines has not been 
accurately determined. Nevertheless, previous studies 
concerning adiponectin have indicated a wide range 
of actions including regulation of energy metabolism, 
modulation of immune system and vascular system. Adi-
ponectin is said to have an influence on glucose and the 
free fatty acids (FFA) metabolism, not in a direct way, but 
rather through sensitisation of tissues to insulin [14, 15, 22, 
23, 30]. Moreover, adiponectin reduces the formation of 
atherosclerosis, suppresses the expression of cell adhesion 
molecules and proinflammatory factors like TNF-a, and 
also restricts macrophages transforming into foam cells. In 
addition, it constrains the release of growth factors, reduc-
ing the proliferation of vascular smooth muscle [14, 15]. 
Adiponectin also plays a role in the central nervous system, 
causes body temperature elevation and stimulates the 
sympathetic nervous system [15, 24, 31]. Taken together, 
these facilities place adiponectin as an anti-inflammatory 
and antiatherosclerotic protein. 
Leptin demonstrates a relationship with body mass 
— it is increased in obesity and decreases as a result 
of weight reduction [7, 32–35]. The central actions of 
the discussed cytokine manifest through its impact 
on hunger and satiety centres; it also boosts energy 
expenditure, working as an anorexogenic factor. In 
addition, leptin affects the pituitary hormonal axes, 
indirectly influencing secretion of glucocorticoids, thy-
roid hormones, androgens and catecholamines [36–38]. 
Moreover, leptin is involved in the activation of the 
inflammatory process [7, 39, 40].
Resistin is a protein that belongs to the found in 
inflammatory zone (FIZZ) family. It is postulated that it 
affects glucose and FFA levels in blood and lowers cell 
insulin sensitivity [41]. All these actions should generate 
insulin resistance [42], but results in this matter remain 
contradictory. It is said that resistin plays a role in the 
formation of early atherosclerotic lesions [11, 39, 43–45].
The main function of insulin is to prevent hypergly-
caemia and provide energy storage, which it does by 
encouraging cell glucose absorption, glycogenesis and 
lipogenesis. According to the vascular system, insulin 
activates transcription factors such as NFkB (nuclear 
factor kappa B), which promote the synthesis of pro-
inflammatory factors involved in atherogenesis [46]. 
These properties contribute to insulin’s role in vascular 
diseases including stroke [47–50].
Material and methods
Subjects
Sixty nine patients with symptoms of their first-ever 
ischaemic stroke, admitted to the stroke subunit of the 
neurology department, were included in this study. 
The study group consisted of 32 men and 37 women 
between the ages of 34 and 95 years (mean 70.2). The 
inclusion criterion was the first-ever ischaemic stroke, 
as confirmed by computer tomography imaging.
All participants underwent a full clinical evaluation 
including measurement of body mass index (BMI) and 
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routine biochemical blood tests. In the study group, 
neurological evaluation was performed using the Bar-
thel ADL index, either on the day of admission or on 
the ninth day of hospitalisation.
Stroke group candidates were excluded if they had 
suffered a hemorrhagic stroke, brain tumour, a stroke 
other than a first-ever stroke, diabetes, hypothyroidism, 
hyperthyroidism, moderate or severe anaemia, renal in-
sufficiency, or dyslipidaemia treated with hypolypemic 
medications. Patients with stroke who died during 
hospital treatment were also excluded.
The control group consisted of 26 individuals 
admitted to hospital in order to undergo endoscopic 
diagnostic procedures. This group included 12 men and 
14 women between the ages of 27 and 82 years (mean 
65 years), who did not meet the exclusion criteria.
Blood sample analyses
Venous blood samples were collected on the admis-
sion day from the antecubital vein. The blood samples 
were centrifugated to obtain serum, which was rapidly 
frozen at -80°C for subsequent analysis. Serum insulin 
concentration was measured by the electrochemilumi-
nescence method. Adiponectin and leptin serum levels 
were determined by the radioimmunoassay method 
(Merck Millipore, Billerica, MA, USA). Resistin serum 
Table I. Characteristics of patients with ischaemic cerebral stroke and control group
Tabela I. Charakterystyka kliniczna chorych z niedokrwiennym udarem mózgu i osób grupy kontrolnej
Ischaemic stroke 
(N = 69)
Controls (N = 26) p value
Age (years) 70.217 (SD ± 13.01) 65.077 (SD ± 13.83)  > 0.05
BMI [kg/m2] 27.35 (SD ± 4.38) 26.01 (SD ± 3.18)  > 0.05
Glucose [mmol/L] 5.46 (SD ± 0.815) 5.02 (SD ± 0.75)  > 0.05
Total cholesterol [mmol/L] 4.99 (SD ± 1.26) 5.01 (SD ± 1.06)  > 0.05
LDL [mmol/L] 3.016 (SD ± 1.07) 3.11 (SD ± 0.99)  > 0.05
HDL [mmol/L] 1.31 (SD ± 0.47) 1.20 (SD ± 0.88)  > 0.05
TSH [µIU/mL] 2.25 (SD ± 2.45) 2.01 (SD ± 2.3)  > 0.05
ESR [mm/h] 24.779 (SD ± 2.38) 11.0 (SD ± 9.0) £ 0.05
CRP [mg/L] 27.70 (SD ± 56.21) 10.0 (SD ± 6.02) £ 0.05
BMI — body mass index; LDL — low density lipoprotein; HDL — high density lipoprotein; TSH — thyroid stimulating hormone; ESR — erythrocyte 
sedimentation rate after 1 h; CRP — C-reactive protein
Table II. Glucose, insulin and HOMA-IR parameters in patients with ischaemic cerebral stroke and in control group
Tabela II. Ocena stężeń insuliny, wskaźnika insulinooporności oraz glikemii u chorych z niedokrwiennym udarem mózgu 
i u osób grupy kontrolnej
Ischaemic stroke Controls p value
Glucose [mmol/L] 5.46 (SD ± 0.815) 5.02 (SD ± 0.75)  > 0.05
Insulin [µU/mL] 51.089 (SD ± 29.13) 17.02 (SD ± 8.1) £ 0.05
HOMA-IR 6.3 (SD ± 0.8) 2.2 (SD ± 0.2) £ 0.05
HOMA-IR — homeostatic model assessment of insulin resistance
Table III. Adiponectin, leptin and resistin blood concentrations in patients with ischaemic cerebral stroke and in control group
Tabela III. Stężenie adiponektyny, leptyny i rezystyny we krwi chorych z niedokrwiennym udarem mózgu i u osób grupy 
kontrolnej
Ischaemic stroke Controls p value
Adiponectin [µg/mL] 15.498 (SD ± 9.604) 14.325 (SD ± 8,868)  > 0.05
Leptin [ng/mL] 14.98 (SD ± 11.325) 10.471 (SD ± 7,245) £ 0.05
Resistin [ng/mL] 28.92 (SD ± 23.62) 12.257 (SD ± 4,21) £ 0.001
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concentration was measured by the ELISA method 
(LINCO Research Inc., St. Charles, MO, USA)
Insulin sensitivity
Insulin sensitivity was determined by homeostatic 
model assessment, with a use of a HOMA-IR calculator 
acquired from the Diabetes Trials Unit of the Oxford 
Centre for Diabetes, Endocrinology and Metabolism 
(http://www.dtu.ox.ac.uk).
Statistical analyses
All acquired data was analysed using Statistica v. 7.1 
(StatSoft Inc., Tulsa, OK, USA) and MedCalc v. 9.02 
(MedCalc Software, Mariakerke, Belgium). For each 
quantitative parameter, basic statistical characteristics 
were made – mean, standard deviation, SEM (standard 
error of the mean), minimal and maximal value, median, 
quartiles 25% and 75%, 95% confidence interval.
Shapiro-Wilk test was performed for evaluation of 
normal distribution of parameters. For intergroup sta-
tistical dependence determination, Student’s t-test was 
used to compare unpaired groups of parameters that 
follow normal distribution. Mann-Whitney U-test was 
used to compare independent groups of parameters that 
did not follow normal distribution. For assessment of 
intergroup correlations, a Spearman Rank Correlation 
test was used for univariate correlation determination, 
and Pearson’s correlation coefficient was used for mul-
tivariate data correlation investigation.
Results
The general characteristics of the stroke survivors’ 
group did not show statistically significant differences 
in basic clinical and biochemical parameters compared 
to the control group. We found differences in the 
ESR (erythrocyte sedimentation rate, 22.779 mm/h 
v. 11 mm/h, p £ 0.05) and CRP values (27.7 mg/L 
v. 10 mg/L, p £ 0.05), which were elevated in the study 
group compared to controls.
We did not observe significant differences in the 
blood glucose concentration between participants and 
the control group. By contrast, we noticed significantly 
higher values of insulin level (51.089 mU/mL v. 17.02 mU/mL, 
p £ 0.05) and insulin resistance index HOMA-IR (6.3 v. 
2.2, p £ 0.05) in the stroke group.
We did not observe significant differences in levels of 
blood adiponectin between the groups. On the contrary, 
we found higher concentrations of leptin (14.98 ng/mL 
v. 10.471 ng/mL, p £ 0.05) and resistin (28.92 ng/mL v. 
12.257 ng/mL, p £ 0.05) in stroke survivors.
Our results show a positive correlation between se-
rum insulin and BMI, leptin and LDL cholesterol levels. 
We also noted a positive link between insulin resist-
ance index and either leptin or BMI. Our study did not 
confirm the existence of a relationship between serum 
resistin and insulin resistance measured by HOMA-IR. 
We found that there was a negative affiliation between 
adiponectin and insulin or HOMA-IR.
We observed a positive correlation between adi-
ponectin and either age or HDL cholesterol. We also 
noted a negative association for adiponectin and the 
severity of stroke assessed by the Barthel scale both 
on admission and on the ninth day of hospitalisation. 
We also revealed a positive bond connecting resistin 
values with CRP level and WBC count. Additionally, 
we found a negative relationship between resistin and 
total cholesterol concentration.
After dividing the study group by sex, we observed 
certain relationships. In the subgroup of men, we 
found a statistically significant positive correlation 
between leptin and insulin and HOMA-IR; a similar 
dependency, although less marked, occurred in women. 
A subset of women was characterised by the existence 
of a negative relation between adiponectin levels and 
insulin or HOMA-IR; similar compounds did not show 
up among men.
Discussion
Chronic hyperglycaemia is a well-known risk factor for 
vascular diseases [49, 51, 52]. Numerous studies have 
dealt with the role of this phenomenon in the acute 
phase of ischaemic stroke [46, 49, 53, 54]. It has been 
found experimentally that an elevated glucose concen-
tration reduces cerebral blood flow during ischaemic 
stroke, with specific intensity in penumbra areas [46]. 
Our study, however, showed no difference in the glu-
cose level between patients and controls, although this 
may be the effect of excluding from analysis people 
suffering from diabetes.
The increase in insulin concentrations observed dur-
ing the acute phase of stroke has also been studied in 
the past [46]. The link between hyperinsulinaemia and 
thrombotic mechanism of stroke has been stated. Our 
results in this regard were consistent with those studies. 
It is interesting though that the difference in insulin did 
not associate with the difference in the glucose level 
among our groups. This fact can be explained by the 
fact of the rapid ascent of insulin demand during the 
acute phase of ischaemic stroke. Intriguing results were 
published by Lindsberg and Roine, suggesting that 
insulin may act as a neuroprotective agent by reducing 
hyperglycaemia and thereby reducing the amount of 
ROS and inflammatory factors [46].
In a prospective study, Wannamethee has shown 
that hyperinsulinaemia is an independent risk factor 
for stroke [54]. In addition, Japanese researchers have 
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demonstrated a relationship between hyperinsulinae-
mia and the propagation of atherosclerotic lesions, 
defined as intima-media thickness in the carotid artery 
[55]. In a similar vein, the results of a 22-year follow-up 
study of Helsinki policemen indicated a role for insulin 
concentration in the development of atherosclerosis 
[56]. Swedish scientists have linked the role of insulin 
in stroke risk elevation with impaired coagulation and 
fibrinolysis systems and activation of PAI-1 by this 
hormone [57].
The results of our study also took into consideration 
the value of HOMA-IR index. This indicator informs as 
to the number of insulin particles needed for glucose to 
enter the cells. Our data demonstrated an increase of 
Table IV. Correlations of insulin concentration and HOMA-IR with clinical data and biochemical tests results in patients 
with ischaemic cerebral stroke
Tabela IV. Korelacje insulinemii i wskaźnika insulinooporności z danymi klinicznymi oraz parametrami biochemicznymi 
u chorych z niedokrwiennym udarem mózgu
Correlate parameters R p value
Insulin BMI 0.362 0.0019
Insulin Leptin 0.472 0.0001
Insulin LDL 0.253 0.0347
Insulin Adiponectin –0.272 0.0319
Insulin Resistin –0.105  > 0.05
Insulin Bartel start –0.008  > 0.05
Insulin Bartel end –0.009  > 0.05
HOMA-IR BMI 0.371 0.0017
HOMA-IR Leptin 0.433 0.0001
HOMA-IR Adiponectin –0.289 0.0225
HOMA-IR Resistin –0.079  > 0.05
HOMA-IR CRP 0.064  > 0.05
Bartel start — Bartel scale evaluation on admission; Bartel end — Bartel scale evaluation on the ninth day following admission
Table V. Correlations of blood adipocytokines concentrations with clinical data and biochemical tests results in patients with 
ischaemic cerebral stroke
Tabela V. Korelacje pomiędzy stężeniami adipocytokin a danymi klinicznymi oraz parametrami biochemicznymi u chorych 
z niedokrwiennym udarem mózgu
Adiponectin [µg/mL] Leptin [ng/mL] Resistin [ng/mL]
R p value R p value R p value
Age (years) 0.363 0.0037 0.133  > 0.05 0.055  > 0.05
BMI [kg/m2] –0.168  > 0.05 0.435 0.0001 0.104  > 0.05
Total cholesterol 
[mmol/L]
0.134  > 0.05 0.039  > 0.05 –0.274 0.0293
LDL [mmol/L] –0.039  > 0.05 –0.023  > 0.05 –0.221  > 0.05
HDL [mmol/L] 0.418 0.0007 0.222  > 0.05 0.059  > 0.05
ESR [mm/h] –0.133  > 0.05 0.016  > 0.05 0.230  > 0.05
CRP [mg/L] –0.08  > 0.05 0.064  > 0.05 0.475 0.0001
WBC [1000/mL] –0.121  > 0.05 0.059  > 0.05 0.330 0.008
Bartel start –0.2669 £ 0.05 –0.1352  > 0.05 –0.1674  > 0.05
Bartel end –0.302 £ 0.05 –0.203  > 0.05 –0.161  > 0.05
BMI — body mass index; LDL — low density lipoproteins; HDL — high density lipoproteins; ESR — erythrocyte sedimentation rate after 1 h; CRP — 
C-reactive protein; WBC — white blood cells; Bartel start — Bartel scale evaluation on admission; Bartel end — Bartel scale evaluation on ninth day 
following admission
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HOMA-IR in the stroke survivors. Moreover, we showed 
positive associations of HOMA-IR with BMI and leptin, 
and a negative association with adiponectin. That puts 
our findings in line with the reports of other research 
groups [30, 48].
We found no differences in adiponectin concentra-
tion between the studied group and controls. These 
results were a surprise to us, because other research-
ers have suggested the presence of low adiponectin 
levels among patients with stroke [25]. On the other 
hand, some authors have confirmed our observation 
[26]. We also noted a positive correlation between 
adiponectin levels and age or HDL cholesterol, and as 
already mentioned, a negative link with insulin and 
HOMA-IR, which is consistent with the data obtained 
by Ryan and Macko [58]. Moreover, analysis of the 
relationship between adiponectin concentration and 
the severity of stroke has shown that high levels of this 
protein are accompanied by a worse neurological state. 
Similar results were published in 2009 by Marousi and 
Theodorou [59]. In our case, the discussed correlation 
disappeared after the division of stroke group based on 
sex, which we believe was due to the small number of 
study participants.
Current publications state the role of adiponectin 
in the pathogenesis of cardiovascular diseases [60, 61]. 
It has been proven that adiponectin levels connect 
with myocardial infarction risk [17], exacerbation of 
coronary artery disease [14] and the risk of restenosis 
after coronary intervention [19]. Low levels of this 
cytokine correlate with progression of atherosclerosis, 
independently of other factors [14, 62]. Some scientists 
have interpreted this as a phenomenon secondary to 
the vascular repair process, in which the decrease in the 
amount of adiponectin is the consequence of accumula-
tion in damaged areas, where it inhibits inflammation 
and atherogenesis [19, 63].
Interesting information about the activity of adi-
ponectin in stroke was provided by Chen, who in an 
experimental study demonstrated that administration 
of exogenous adiponectin to rats with ischaemic stroke 
causes reduction of central nervous system damage. 
This phenomenon of neuroprotection is explained by 
the inhibition of the release of proinflammatory factors 
— TNF-a and IL-6, it also decreases NFkB activity [64].
The relation between adiponectinaemia and stroke 
risk was proposed in the PROSPER (Prospective Study 
of Pravastatin in the Elderly at Risk) study [65], in which 
hypoadiponectinaemia was indicated as a risk factor 
for cerebral ischaemia. These results are contrary to 
data published by Soderberg [66] and Matsumoto [26]. 
This difference may be explained by the fact that the 
PROSPER study included patients on statin therapy, 
which can elevate adiponectin levels.
Our results show higher concentrations of leptin 
in stroke survivors. Moreover, we found a positive 
correlation between leptin and BMI, insulin level or 
HOMA-IR. These findings suggest a role of leptin in the 
development of insulin resistance, which is consistent 
with previous reports [9, 40, 66, 67]. The physiological 
secretion of leptin is though dependent on insulin ac-
tion on adipocytes [40]. However, the increase of body 
fat, plasma FFA, androgens and glucocorticoids, may 
cause hyperleptinaemia in an insulin independent way. 
Many scientists have claimed a link between leptin 
and vascular diseases [40, 65, 68, 69]. Wolk et al. also 
demonstrated a relationship between hyperlepitnae-
mia and the risk of cerebral ischaemia, which was 
independent of other risk factors [70]. Similar results 
were presented by Soderberg [66, 67]. The proposed 
mechanism through which leptin acts is to influence 
the sympathetic nervous system, resulting in an eleva-
tion of blood pressure [40], as well as a direct effect on 
the vascular wall [66], endothelium [58, 66, 68, 71] and 
Table VI. Correlations of adiponectin and leptin blood concentrations with insulin level HOMA-IR and BMI in men and 
women with ischaemic cerebral stroke
Tabela VI. Korelacje pomiędzy stężeniami adiponektyny i leptyny we krwi a stężeniem insuliny, wskaźnikiem HOMA oraz 
BMI u mężczyzn i kobiet z niedokrwiennym udarem mózgu
Men with ischaemic stroke Women with ischaemic stroke
Correlated parameters R p value Correlated parameters R p value
Leptin [ng/mL] HOMA-IR 0.705  < 0.0001 Leptin [ng/mL] HOMA-IR 0.43 0.013
Leptin [ng/mL] Insulin [µU/mL] 0.666  < 0.0001 Leptin [ng/mL] Insulin [µU/mL] 0.481 0.0053
Leptin [ng/mL] BMI [kg/m2] 0.499 0.0042 Leptin [ng/mL] BMI [kg/m2] 0.45 0.0088
Adiponectin [µg/mL] HOMA-IR 0.002  > 0.05 Adiponectin [µg/mL] HOMA-IR –0.539 0.0018
Adiponectin [µg/mL] Insulin [mU/mL] –0.07  > 0.05 Adiponectin [µg/mL] Insulin [µU/mL] –0.484 0.0057
Adiponectin [µg/mL] BMI [kg/m2] –0.017  > 0.05 Adiponectin [µg/mL]  BMI [kg/m2] –0.3850 0.032
HOMA-IR — homeostatic model assessment of insulin resistance; BMI — body mass index
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thrombocytes [40, 66]. Surprisingly, Valerio and Dos-
sena have presented data suggesting that an increase 
of leptin level during the acute phase of a stroke may 
act as a neuroprotective factor protecting the brain from 
ischaemic damage [72].
Our results revealed the presence of higher con-
centrations of resistin in the study group than in the 
control group. In addition, we noted a negative cor-
relation between resistin and total cholesterol, while 
it was positive with CRP and WBC count. This may 
display the role of resistin in inflammatory response. 
Therefore we did not observe a link connecting resistin 
with insulin resistance, as has been postulated in animal 
studies [73], but this is consistent with other human 
study results [74–76]. With regard to stroke, Japanese 
researchers presented an association between resistin 
concentration and the severity of stroke [77]. This found 
no confirmation in our results.
After the division of studied group by sex, we re-
vealed significant differences in adiponectin and leptin 
concentrations, which were both higher in women. It is 
interesting that the relationship between adiponectin 
and Barthel index score disappeared after the split. 
The lack of a significantly higher incidence of stroke 
in females, despite higher leptin concentrations, is 
explained in two popular theories. The first says that 
women are less sensitive to leptin than men [78]. The 
second suggests that the incidence of stroke is rather 
related to the leptin/adiponectin ratio, which is prefer-
able in females, because of the antagonistic actions of 
both cytokines [66].
Conclusions
The role of insulin and adipocytokines in the patho-
genesis and mechanism of stroke still remains not fully 
understood. However, we suggest a significant influ-
ence of these particles on the vascular system, including 
cerebral circulation. 
Our study showed that hyperinsulinaemia and 
insulin resistance measured by HOMA-IR favour the 
occurrence of a stroke. Among adipocytokines, we 
recorded the role of leptin and resistin in the stroke 
phenomenon, but we found no similar dependence in 
relation to adiponectin. In addition, we noted a strong 
correlation between resistin and proinflammatory fac-
tors, which confirms the role of this protein in acute 
phase reactions. 
Among our patients, we have also found a negative 
correlation of adiponectin concentration with the stroke 
severity measured using the Barthel index. This fact was 
a surprise. However, it is possible that the interpretation 
should take into consideration the age of our patients. 
Moreover, we have observed that women do not present 
a higher stroke incidence, despite higher leptin levels in 
comparison to men, which may be connected with the 
antagonistic actions of leptin and adiponectin, which 
is also elevated.
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